{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:47:07Z","timestamp":1790221627488,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01686-2","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:05:02Z","timestamp":1742328302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mirvetuximab soravtansine: current and future applications"],"prefix":"10.1186","volume":"18","author":[{"given":"Beihua","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"8","key":"1686_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681\u201392.","journal-title":"Ann Oncol"},{"issue":"3","key":"1686_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/ijgc-2022-003701","volume":"33","author":"A Chelariu-Raicu","year":"2023","unstructured":"Chelariu-Raicu A, et al. Integrating antibody drug conjugates in the management of gynecologic cancers. Int J Gynecol Cancer. 2023;33(3):420\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"1686_CR3","first-page":"CD012464","volume":"8","author":"GU Eleje","year":"2018","unstructured":"Eleje GU, et al. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018;8(8):CD012464.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1686_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","volume":"17","author":"Q Wei","year":"2024","unstructured":"Wei Q, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1686_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, et al. Safety and activity of Mirvetuximab Soravtansine (IMGN853), a folate receptor Alpha-Targeting Antibody-Drug conjugate, in Platinum-Resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase I expansion study. J Clin Oncol. 2017;35(10):1112\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1686_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, et al. Phase III, randomized trial of Mirvetuximab Soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757\u201365.","journal-title":"Ann Oncol"},{"key":"1686_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","volume":"170","author":"L Gilbert","year":"2023","unstructured":"Gilbert L, et al. Safety and efficacy of Mirvetuximab Soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023;170:241\u20137.","journal-title":"Gynecol Oncol"},{"issue":"13","key":"1686_CR8","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, et al. Efficacy and safety of Mirvetuximab Soravtansine in patients with Platinum-Resistant ovarian Cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436\u201345.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1686_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","volume":"151","author":"KN Moore","year":"2018","unstructured":"Moore KN, et al. Safety and activity findings from a phase 1b escalation study of Mirvetuximab Soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018;151(1):46\u201352.","journal-title":"Gynecol Oncol"},{"key":"1686_CR10","doi-asserted-by":"crossref","unstructured":"Alvarez Secord A et al. The efficacy and safety of mirvetuximab soravtansine in FRalpha-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann Oncol, 2024.","DOI":"10.1016\/j.annonc.2024.11.011"},{"issue":"23","key":"1686_CR11","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"issue":"2","key":"1686_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ygyno.2021.08.021","volume":"163","author":"C Saccardi","year":"2021","unstructured":"Saccardi C, et al. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC). Gynecol Oncol. 2021;163(2):364\u201370.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1686_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/AOG.0b013e3181ec5fc1","volume":"116","author":"JS Berek","year":"2010","unstructured":"Berek JS, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010;116(3):733\u201343.","journal-title":"Obstet Gynecol"},{"issue":"17","key":"1686_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.21.02016","volume":"40","author":"MP Steenbeek","year":"2022","unstructured":"Steenbeek MP, et al. Risk of peritoneal carcinomatosis after Risk-Reducing Salpingo-Oophorectomy: A systematic review and individual patient data Meta-Analysis. J Clin Oncol. 2022;40(17):1879\u201391.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1686_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/IGC.0000000000000639","volume":"26","author":"WY Chay","year":"2016","unstructured":"Chay WY, et al. Outcomes of incidental fallopian tube High-Grade serous carcinoma and serous tubal intraepithelial carcinoma in women at low risk of hereditary breast and ovarian Cancer. Int J Gynecol Cancer. 2016;26(3):431\u20136.","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"1686_CR16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1111\/1471-0528.17919","volume":"131","author":"S Negri","year":"2024","unstructured":"Negri S, et al. Diagnosis and management of isolated serous tubal intraepithelial carcinoma: A qualitative focus group study. BJOG. 2024;131(13):1851\u201361.","journal-title":"BJOG"},{"issue":"2","key":"1686_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00404-023-06919-8","volume":"308","author":"J van der Ven","year":"2023","unstructured":"van der Ven J, et al. A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany. Arch Gynecol Obstet. 2023;308(2):527\u201334.","journal-title":"Arch Gynecol Obstet"},{"key":"1686_CR18","doi-asserted-by":"publisher","first-page":"1254532","DOI":"10.3389\/fimmu.2023.1254532","volume":"14","author":"J Mai","year":"2023","unstructured":"Mai J, et al. Therapeutic strategies targeting folate receptor alpha for ovarian cancer. Front Immunol. 2023;14:1254532.","journal-title":"Front Immunol"},{"issue":"8","key":"1686_CR19","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/ijgc-2024-005861","volume":"34","author":"A Gonzalez-Martin","year":"2024","unstructured":"Gonzalez-Martin A. Antibody-drug conjugate targeting folate receptor alpha: a new milestone in personalized medicine for high-grade serous ovarian cancer. Int J Gynecol Cancer. 2024;34(8):1126\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"1686_CR20","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, et al. Mirvetuximab Soravtansine in FRalpha-Positive, Platinum-Resistant ovarian Cancer. N Engl J Med. 2023;389(23):2162\u201374.","journal-title":"N Engl J Med"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01686-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:05:06Z","timestamp":1742328306000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01686-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1686"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01686-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors\u2019 own work, unpublished.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}